Allegra

Allegra is an allergy-relief medicine brand marketed primarily for consumers seeking relief from allergic rhinitis and related symptoms. Its principal active ingredient is fexofenadine, a second-generation antihistamine commonly used to relieve sneezing, runny nose, itchy nose or throat, and itchy or watery eyes. Compared with some older antihistamines, fexofenadine is generally positioned as less likely to cause drowsiness, although effects and precautions depend on the formulation, the user’s condition, and local labeling. In the United States and some other markets, Allegra products are sold over the counter and include adult formulations, children’s products, and selected products aimed at nasal or eye symptoms. The brand is currently part of Sanofi’s consumer-health business. Product names, formulations, dosages, and marketing authorization holders can vary by country, so local packaging and regulatory labeling should be consulted.

Allegra is an allergy-medicine brand centered on fexofenadine. Fexofenadine is the active metabolite of terfenadine and was developed in the context of seeking an antihistamine with less sedation and improved cardiac-safety characteristics than certain earlier products. Allegra subsequently developed primarily as an over-the-counter brand in the United States and other markets, offering products for adults and children and, in selected formulations, products containing a decongestant or aimed at nasal and eye symptoms. The brand later became part of Sanofi’s consumer-health portfolio. Approval dates, formulations, product names, and brand-rights arrangements differ across countries, so its international history cannot be reduced to one uniform timeline. The supplied material is insufficient to verify the brand’s first launch year or particular acquisition and licensing milestones, so unverified dates and financial figures are omitted.

An over-the-counter antihistamine brand positioned as a second-generation antihistamine that relieves allergy symptoms with less drowsiness.

• Allegra AllergyAntihistamine

  Allegra’s core allergy-relief line uses fexofenadine as its principal active ingredient and is intended for symptoms associated with seasonal and perennial allergies. Common formulations include tablets, while dosage and age indications vary by market and version.

• Allegra-DAntihistamine and decongestant combination

  Allegra-D is a combination line pairing an antihistamine with a decongestant, intended for allergy symptoms accompanied by nasal congestion. Decongestants may carry additional contraindications and restrictions, so local labeling or professional advice should be followed.